<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Methionine S-adenosyltransferase 2A (MAT2A) is the catalytic subunit for synthesis of S-adenosylmethionine (<z:chebi fb="75" ids="15414">SAM</z:chebi>), the principal <z:chebi fb="36" ids="29309">methyl</z:chebi> donor in many biological processes </plain></SENT>
<SENT sid="1" pm="."><plain>MAT2A is up-regulated in many <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, including <z:hpo ids='HP_0002896'>liver cancer</z:hpo> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and is a potentially important drug target </plain></SENT>
<SENT sid="2" pm="."><plain>We developed a family of fluorinated N,N-dialkylaminostilbene agents, called FIDAS agents, that inhibit the proliferation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells in vitro and in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>Using a biotinylated FIDAS analogue, we identified the catalytic subunit of MAT2A as the direct and exclusive binding target of these FIDAS agents </plain></SENT>
<SENT sid="4" pm="."><plain>MAT2B, an associated regulatory subunit of MAT2A, binds indirectly to FIDAS agents through its association with MAT2A </plain></SENT>
<SENT sid="5" pm="."><plain>FIDAS agents inhibited MAT2A activity in <z:chebi fb="75" ids="15414">SAM</z:chebi> synthesis, and <z:mpath ids='MPATH_63'>depletion</z:mpath> of MAT2A by shRNAs inhibited <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell growth </plain></SENT>
<SENT sid="6" pm="."><plain>A novel FIDAS agent delivered orally repressed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> xenografts in athymic <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that FIDAS analogues targeting MAT2A represent a family of novel and potentially useful agents for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment </plain></SENT>
</text></document>